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Abstract Accumulation of beta-amyloid (Aβ) in the extra-
cellular space, which is one of the hallmarks of Alzheimer’s
disease (AD), depends on the balance between its synthesis
and clearance. The physiological role of extracellular chaper-
ones, capable of affecting early events in the amyloid cascade,
is increasingly being investigated by many research groups.
Among these proteins, we focused on haptoglobin, which we
recently found to form a complex with beta-amyloid in brain
tissues or cerebrospinal fluids from patients with AD. We also
previously reported that haptoglobin increases with age in rat
hippocampus.Major aim of this studywas to evaluate whether
haptoglobin influences Aβ interaction with astrocytes and its
internalization into these cells. Haptoglobin effect on Aβ-
induced cell death was also explored. We report here that
haptoglobin impairs Aβ uptake by human glioblastoma–as-
trocytoma cell line U-87 MG and limits the toxicity of this
peptide on these cells. Of note, our data also show that Aβ can
stimulate haptoglobin release by astrocyte cell lines. The study
of the risk of developing AD should be focused not only on
the analysis of Aβ but also on the level of critical ligands, such
as haptoglobin, able to influence peptide aggregation or
clearance.
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Introduction
Alzheimer’s disease (AD) is the most common form of age-
related dementia in the elderly. Major neuropathological and
neurochemical hallmarks of AD include the extracellular ac-
cumulation of amyloid-β peptide (Aβ) in brain senile plaques
and the intracellular formation of neurofibrillary tangles com-
posed of hyperphosphorylated Tau protein (Huang and Jiang
2009). Aggregation of Aβ into oligomers and fibrils was
hypothesized to lead to a pathological cascade resulting in
synaptic dysfunction, neuronal loss, and, ultimately, cognitive
decline (Holtzman et al. 2011). Accumulation of Aβ in brain
senile plaques results from the imbalance between production
and clearance of Aβ (Janciauskiene et al. 1998). Therefore, a
better characterization of the mechanisms underlying Aβ
elimination from the brain may lead to insights into the
pathogenesis of the disease and reveal novel therapeutic tar-
gets. In fact, Aβ clearance from the central nervous system
(CNS), not only its production, was shown to be impaired in
individuals with late-onset AD (Mawuenyega et al. 2010).
Several clearance pathways for Aβ exist in the CNS, includ-
ing cellular uptake and lysosomal degradation, transport
across the blood–brain barrier (BBB), extracellular degrada-
tion by proteolytic enzymes, and bulk flow drainage of inter-
stitial fluid and cerebrospinal fluid (CSF) (Bell et al. 2007;
Deane et al. 2008; Basak et al. 2012; Castellano et al. 2012;
Iliff et al. 2012). Although current evidence suggests that
astrocytes might play a protective role in AD by shielding
neurons from the toxic effects of extracellular senile plaques
(Guénette 2003), the exact role of these cells in amyloid
clearance needs further investigations. Recently, it has been
reported that activated astrocytes can internalize and degrade
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Aβ (Verghese et al. 2013; Li et al. 2014; Mulder et al. 2014)
probably in the attempt to reduce Aβ exposure to neurons.
Next to Aβ, several other proteins called amyloid-associated
proteins (AAPs), such as serum amyloid P, complement factor
C1q, alpha1-antichymotrypsin, haptoglobin (Hpt), apolipo-
protein J (ApoJ), and apolipoprotein E (ApoE) are known to
co-localize with Aβ in the amyloid plaque (Veerhuis et al.
2003; Yerbury et al. 2005). Due to their proximity with senile
plaques and to their capacity to interact with Aβ, AAPs may
be involved in AD pathogenesis. The acute phase protein Hpt
is mainly synthesized in the liver and is so far known for its
role in hemoglobin binding and transport to the liver (Quaye
2008). Hpt was initially identified as a marker of BBB dys-
function (Chamoun et al. 2001). Further, some studies pointed
out that this protein may be produced in the brain in response
to different stress stimuli (Lee et al. 2002; Borsody et al. 2006;
Zhao et al. 2009), and increased level of Hpt was found in
CSF from patients with AD (Johnson et al. 1992; Yerbury and
Wilson 2010) or other neurodegenerative diseases such as
Parkinson’ and Huntington’s disease (Argüelles et al. 2010;
Huang et al. 2011). Hpt was reported to co-localize with
amyloid plaques in AD (Powers et al. 1981), to bind Aβ and
inhibit Aβ fibril formation in vitro (Wilson et al. 2008;
Yerbury et al. 2009). Furthermore, we recently provided evi-
dence that Hpt modulates ApoE-mediated cholesterol traffick-
ing in neuroblastoma cell lines and that its concentration
increases with the age in rat hippocampus as well as in human
CSF (Spagnuolo et al. 2014a). The ability of Hpt to bind Aβ
raises the possibility that this protein might influence Aβ
homeostasis and/or Aβ interaction with brain cells. The aim
of this study was to evaluate whether Hpt influences Aβ
interaction with astrocytes and its internalization. Since Aβ
accumulation has been reported as a key event in Aβ-
mediated cell degeneration (Verbeek et al. 1997), Hpt effect
on Aβ-induced cell death was also explored.
Materials and Methods
Materials
Bovine serum albumin (BSA) fraction V, gelatin, rabbit anti-
human Hpt IgG, mouse anti-β actin IgG, goat anti-rabbit
horseradish peroxidase-conjugated IgG (GAR-HRP), goat
anti-mouse horseradish peroxidase-conjugated IgG (GAM-
HRP), Crystal Violet, and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), were purchased from
Sigma-Aldrich (St. Louis, MO, USA). The dye reagent for
protein titration, enhanced chemiluminescence (ECL) re-
agents, and the polyvinylidene difluoride (PVDF) membrane
were from Bio-Rad (Bio-Rad, Hercules, CA, USA).
Polystyrene 96-well enzyme-linked immunosorbent assay
(ELISA) MaxiSorp plates were purchased from Nunc
(Roskilde, Denmark). Recombinant human ApoE3 was from
PeproTech (London, UK). Kodak Biomax light film,
Sephacryl S-200, CNBr-activated Sepharose 4 Fast Flow,
and Blue Sepharose 6 Fast Flow resins were from GE-
Healthcare Life Sciences (Milan, Italy). Dulbecco’s modified
Eagle’s medium (DMEM) and fetal bovine serum (FBS) were
from BioWhittaker (Verseviers, Belgium). L-Glutamine,
TrypLE Express, penicillin, and streptomycin were from
Gibco (Life Technologies Italy, Monza, Italy). Cell culture
flasks (25 cm2), 96-well cell culture plates, 24-well culture
plates, and sterile pipettes of Beckton-Dickinson (Milan, Italy)
were used.
Purification of Hpt
Hpt was isolated from plasma of healthy subjects (phenotype
1–1) by a multi-step purification procedure as previously
reported (Cigliano et al. 2009). Hpt was over 98 % pure, as
assessed by sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis (SDS-PAGE) and densitometric analysis of
Coomassie-stained bands. The molarity of purified Hpt was
determined by measuring the protein concentration (Bradford
1976) and calculating the molecular weight of the monomer
αβ as previously described (Cigliano et al. 2003).
Aβ Preparation
Human Aβ1–42 (GL Biochem, Shanghai; purity>95 % as
assessed by HPLC) was produced by chemical synthesis. In
order to obtain a solution free of aggregates and fibrils, the
lyophilized peptide was treated with 1,1,1,3,3,3-hexafluoro-2-
propanol (HFIP) (Stine et al. 2003). After HFIP evaporation
under nitrogen stream, the peptide was resuspended in anhy-
drous dimethyl sulfoxide, sonicated for 20 min (bath sonicator
model 3200MH; Soltec), and its concentration was verified by
a colorimetric assay (Bradford 1976) using insulin as standard
for calibration.
Cell Culture
The human glioblastoma–astrocytoma cell line U-87 MGwas
kindly provided by the Institute of Genetics and Biophysics
(CNR, Naples, Italy). U-87MG cells express the astrocyte cell
marker glial fibrillary acidic protein and are widely used as
astrocyte model in vitro (Bertrand et al. 2009; Chen et al.
2010;Moser and Fritzler 2010; Li et al. 2014). Cells (400,000)
were seeded in T-25 tissue culture flasks (25 cm2 surface) and
grown in DMEM supplemented with 10 % FBS, 2 mM L-
glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin
(complete medium) at 37 °C, under humidified atmosphere of
5 % CO2 in air. The medium was changed twice a week, and
cells were sub-cultivated when confluent.
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Aβ Binding to U-87MG by ELISA
Aβ ability to bind U-87 MG cell line was evaluated by
ELISA. Cells were seeded into a 96-well plate (15,000 cells/
well) and cultured for 20 h in complete medium. Then, the
cells were washed with phosphate-buffered saline (PBS) and
fixed by incubation (30 min, 4 °C) with 0.3 % glutaraldheyde
in PBS. After washing with PBS, the wells were blocked with
PBS containing 1 % BSA (overnight, 4 °C), and then incu-
bated (2 h, 37 °C) with different amounts of Aβ1–42 (0.5, 1,
2.5, 5, 10, or 20 μM in PBS). The amount of Aβ bound to
cells was measured by treatment with 50 μl of mouse anti-Aβ
IgG 6E10 (1:2,000 dilution in PBS; 1 h, 37 °C), followed by
50 μl of GAM-HRP IgG (1:6,000 dilution; 1 h, 37 °C) and
color development at 492 nm. Absorbance values were con-
verted to the percent of the value obtained in the presence of
the higher amount of Aβ used in the assay (assumed as 100 %
of binding). Data were analyzed by a nonlinear regression fit
algorithm (GraphPad Prism v 5.01) for calculating the equi-
librium binding constant (Kd).
In order to evaluate the effect of Hpt on Aβ binding to
cells, U-87 MG, after blocking, were incubated (2 h, 37 °C)
with aliquots (55 μl) from mixtures containing 4 μM Aβ1–42
and different concentrations of Hpt (0, 0.04, 0.08, 0.4, 1.2, 3,
or 6 μM). The amount of Aβ1–42 bound to cells was measured
by incubation with mouse anti-Aβ IgG 6E10 followed by
GAM-HRP IgG as above-described. Absorbance values were
converted to the percent of the value obtained in the absence
of Hpt.
Aβ Internalization into Astrocytes Cell Line
U-87 MG were cultured (96-well plates; 15,000 cells/well) in
complete medium for 20 h. After medium removal, cells were
rinsed with DMEM and incubated (1, 1.5, 3, 6, or 20 h, 37 °C)
in DMEM containing 5 μM Aβ1–42. At each time point,
media samples were collected and cleared of any cellular
debris by centrifugation (400×g, 5 min). The cells were ex-
tensively washed with DMEM, detached by treatment (5 min)
with 50 μl of trypsin (TrypLE Express, Gibco), which also
removes Aβ bound to cell membrane (Verghese et al. 2013),
lysed with RIPA buffer (150mMNaCl, 50mMTris–HCl, 1%
NP-40, 0.5 % sodium deoxycholate, pH 8) containing Tissue
Protease Inhibitor Cocktail (Sigma-Aldrich, 1:200, v/v), and
finally centrifuged (12,000×g, 30 min). Protein concentration
in cell lysates was thenmeasured (Bradford 1976). Aliquots of
media samples and cell lysates were analyzed by electropho-
resis on 16 % polyacrylamide gel, under denaturing but non-
reducing conditions followed by Western blotting, and by
ELISA for measuring Aβ concentration, as described below.
The effect of Hpt on Aβ uptake by astrocytes was evalu-
ated by incubating (1.5, 3, 6, or 20 h, 37 °C) U-87 MG in
DMEMcontaining 5μMAβ1–42 in the absence or presence of
1.6 μM Hpt. At each time point, cell culture supernatants and
cell lysates were collected and then analyzed by electropho-
resis on 4–20 % polyacrylamide gel, under denaturing but
non-reducing conditions (4–20 PAGE-D) followed by
Western blotting, and by ELISA.
In order to compare Hpt and ApoE effect on Aβ uptake by
astrocytes, U-87MGwere incubated (1.5, 3, 6, or 20 h, 37 °C)
in DMEM containing 5 μM Aβ1–42 and 1.6 μM Hpt, or
1.6 μM ApoE, or 1.6 μM Hpt and 1.6 μM ApoE. At each
time point, cell culture supernatants and lysates were collected
and analyzed by both Western blotting and ELISA. The ex-
periment was carried out using liposome-embedded ApoE, as
this apolipoprotein, in brain, is mostly associated with HDL-
like particles (Vance and Hayashi 2010). Liposomes contain-
ing ApoE3 (ApoE/lecithin=1:133 molar contribution, namely
LipoE3) were prepared by the cholate dialysis method (Chen
and Albers 1982; Spagnuolo et al. 2014b).
The dose–effect of Hpt was assessed by incubating the cells
(3 h, 37 °C) in DMEM containing 5 μMAβ1–42 and different
amounts of Hpt (0, 0.5, 1.6, or 3 μM). At the end of incuba-
tion, media samples and cell lysates were analyzed byWestern
blotting and ELISA.
Electrophoresis and Western Blotting
Aliquots of supernatants (20 μl), collected from U-87 MG
incubated with Aβ1–42 in the absence or presence of Hpt, were
treated with 3× O’Farrell buffer without β-mercaptoethanol
(Spagnuolo et al. 2014b) and then analyzed by electrophoresis
(on 16 % or on 4–20 % polyacrylamide gel) under denaturing
but non-reducing conditions, followed by Western blotting.
After proteins transfer onto PVDF membrane (1 h, under
electric field), the membrane was rinsed in T-TBS (130 mM
NaCl, 20 mM Tris–HCl, 0.05 % Tween 20, pH 7.4) and
blocked with T-TBS containing 5 % non-fat milk (overnight,
4 °C). The membrane was then incubated (1 h, 37 °C) with
mouse anti-Aβ IgG 6E10 (1:4000 dilution in T-TBS contain-
ing 0.25 % non-fat milk), followed by GAM-HRP IgG
(1:20,000 dilution; 1 h, 37 °C), for revealing antigens contain-
ing Aβ epitopes. The immunocomplexes were detected by
the ECL detection system. The influence of Hpt on the
formation of Aβ aggregates was investigated by incubating
(0–20 h, 37 °C) 5 μMAβ1–42 in DMEMwithout cells, in the
absence or presence of 1.6 μM Hpt. Aliquots of media
samples were then analyzed 4–20 PAGE-D followed by
Western blotting.
Samples (8 μg) of U-87 MG lysates were analyzed by 4–
20 % PAGE-D and immunoblotting, essentially as described
above for supernatants. In particular, Aβ was revealed by
incubation (overnight at 4 °C) with mouse anti-Aβ IgG
6E10 (1:500 dilution), followed by GAM-HRP IgG (1:1500
dilution; 1 h, 37 °C), and ECL staining. In some experiments,
after Aβ detection, the membrane was extensively washed
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with T-TBS and submerged in stripping buffer (0.4 M NaOH,
45 min, room temperature) for reprobing with anti-β-actin. β-
Actin was revealed by incubation with mouse anti-β-actin
IgG (1:500 dilution; 1 h, 37 °C), followed by GAM-HRP
IgG (1:2000 dilution; 1 h, 37 °C), and ECL staining.
Quantitative densitometry was then carried out by analyzing
the digital images of membranes by the Gel-Pro Analyzer
software (Media Cybernetics, Silver Spring, MA, USA).
Band intensities were calculated as integrated optical density
(IOD).
Enzyme-Linked Immunosorbent Assay Aβ concentration in
supernatants and cell lysates of U-87 MG was measured by
ELISA. Samples were diluted (supernatants, 1:1000, 1:3000,
and 1:6000; cell lysates, 1:100, 1:300, and 1:1000) with
coating buffer (7 mM Na2CO3, 17 mM NaHCO3, and
1.5 mM NaN3, pH 9.6) and incubated in the wells of a
microtiter plate (overnight, 4 °C). The assay was performed
as previously published (Cigliano et al. 2009) by using mouse
anti-Aβ IgG 6E10 (1:500 dilution in T-TBS containing
0.25 % BSA) followed by 50 μl of GAM-HRP IgG (1:6000
dilution).
Analysis of Aβ Effect on Cell Survival
U-87MGwere seeded into 96-well plate (5000 cells/well) and
cultured for 20 h in complete medium. Cells were then rinsed
with DMEM and incubated (24 h, 37 °C) in DMEM contain-
ing different amounts of Aβ1–42 (0, 0.5, 1.5, 3, 6, 10, or
15 μM). Cell survival was evaluated byMTT reduction assay,
by incubating the wells with 100 μl of MTT (0.5 mg/ml in
DMEM without Phenol Red; 3 h, 37 °C). After incubation,
100 μl of a solution containing 0.1 M HCl in isopropanol was
added to eachwell. Absorbance at 595 nmwas thenmeasured.
The data were expressed as percentage of cell survival, as-
suming the absorbance value from cells cultured in the ab-
sence of Aβ as 100 %.
The effect of Hpt was evaluated by incubating (24 h, 37 °C)
the cells in DMEM containing Aβ1–42 (6 μM) and different
amounts of Hpt (0, 0.15, 0.3, 0.6, or 1.2 μM). Cell survival
was thenmeasured byMTTassay, and byCrystal Violet assay,
and data were expressed as cell survival percentage.
Hpt Synthesis and Secretion by U-87 MG Cell Line
U-87 MG were seeded into 24-well plate (100,000 cells/well)
in complete medium and cultured for 20 h. After medium
removal, cells were rinsed with DMEM and incubated (10 h,
37 °C) in DMEM containing different amounts of Aβ1–42 (0,
3, or 6 μM). Media samples were collected, centrifuged
(400×g, 5 min), and finally concentrated 7-fold with centrif-
ugal evaporator. Cells were extensively washed with DMEM,
detached by treatment with trypsin, washed with ice-cold
PBS, and finally lysed with RIPA buffer (supplemented with
Tissue Protease Inhibitor Cocktail, 1:200, v/v). Aliquots of cell
culture supernatants (40 μl) or lysates (28 μg) were fraction-
ated by electrophoresis on 15 % polyacrylamide gel, under
denaturing and reducing conditions (Spagnuolo et al. 2014b).
After protein transfer onto PVDF membrane, Hpt was re-
vealed by incubation (1 h, 37 °C) with rabbit anti-human
Hpt IgG (1:500 dilution), followed by GAR-HRP IgG
(1:3000 dilution; 1 h, 37 °C) and ECL staining.
For cell lysates analysis, the membrane was extensively
washed with T-TBS, after Hpt detection, and submerged in
stripping buffer for reprobing with anti-β-actin. After washing
with T-TBS, the membrane was incubated (1 h, 37 °C) with
mouse anti-β-actin IgG (1:500 dilution), followed by GAM-
HRP IgG (1 :2000 d i l u t i on ; 1 h , 37 °C) . The
immunocomplexes were detected by the ECL detection sys-
tem, and densitometric analysis of the signal was carried out.
Statistical Analysis In all experiments, samples were proc-
essed in triplicate, and data were expressed as mean value±
SEM. The program “GraphPad Prism 5.01” (GraphPad
Software, San Diego, CA, USA) was used to perform regres-
sion analysis, Student’s t test, for comparing two groups of
data, and one-way ANOVA, followed by Tukey’s test, for
multiple group comparisons. P<0.05 was set as indicating
significance.
Results
Hpt Influence on Aβ Binding to Astrocytes
Aβ binding and uptake by primary astrocytes, as well as byU-
87 MG cell line, was previously described (Wyss-Coray et al.
2003; Nielsen et al. 2009, 2010; Li et al. 2014), and both the
low-density lipoprotein receptor (LDLR) and the LDLR-
related protein-1 (LRP-1) were reported to act as Aβ receptors
(Nagele et al. 2003; Fuentealba et al. 2010; Basak et al. 2012;
Kanekiyo et al. 2012). Further, it was recently published that
LRP1 is involved in Aβ internalization in U-87 MG cells (Li
et al. 2014). A preliminary cell-based ELISA was performed
to evaluate the efficiency of Aβ binding to U-87 MG, in our
experimental conditions. To this aim, the cells, after
glutaraldheyde fixation, were incubated with different
amounts of Aβ1–42 (0.5–20 μM). As shown in Fig. 1a, Aβ
was able to bind astrocytes at any concentration assayed. The
amount of peptide bound to cells increased with the concen-
tration of Aβ in the incubation medium (p<0.01), and the
binding plateau was reached at 10 μM. The Kd of Aβ binding
to astrocyte, calculated from nonlinear regression fit, was
1.761±0.289 μM.
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As Aβ interaction with cell surface is crucial for peptide
uptake and intracellular degradation (Paresce et al. 1996;
Nagele et al. 2003; Wilhelmus et al. 2007), we investigated
whether Hpt, due to its interaction with Aβ, influences the
binding of this peptide to U-87 MG astrocyte line. In order to
assess whether Hpt affects Aβ binding to astrocytes, the cells
were incubated with mixtures containing 4 μM Aβ1–42 and
different amounts of Hpt (0–6 μM, corresponding to 0–1.5
molar excess over the concentration of Aβ). As shown in
Fig. 1b, Aβ binding to the fixed cells significantly decreased
(p<0.01) as the amount of Hpt in the incubation mixture
increased. In particular, Aβ binding to astrocytes was reduced
of 30% (p=0.003) by 0.04μMHpt and of 48% (p=0.002) by
0.08 μMHpt (a concentration about 50-fold lower than Aβ in
the mixture). Further, the binding dropped down to 9 and 6 %
in presence of 3 and 6 μM Hpt, respectively (p<0.001). The
concentration of Hpt producing half-maximal inhibition
(IC50) of Aβ binding to astrocyte, calculated from nonlinear
regression fit, was 80.5 nM.
Altogether, our results, although concerning cells fixed
with glutaraldheyde, which might affect their surface proper-
ties, suggest that Hpt strongly interferes with Aβ binding to
astrocyte cell line, likely by displacing the peptide from its cell
receptor and/or by reducing peptide aggregates formation, and
this effect is more pronounced, when the Hpt/Aβ ratio
increases.
U-87 MG Cell Line Takes up and Degrades Soluble Aβ1–42
In order to investigate the contribution of astrocytes to the
clearance of soluble Aβ, U-87 MG cells were incubated with
5 μM Aβ1–42 for different times (1–20 h). Aliquots of super-
natants and cell lysates, collected at each time point, were then
analyzed byWestern blotting and by ELISA for revealing and
titrating Aβ1–42. Western blotting analysis revealed that solu-
ble Aβ1–42 in the cell culture supernatant decreased in a time-
dependent manner (Fig. 2a), thus showing that this cell line is
able to clear Aβ1–42 from extracellular milieu. The peptide
concentration, assessed by ELISA, was found to linearly
decrease from 1 to 6 h of incubation with cells (Fig. 2b; r=
−0.97; p=0.04). In particular, Aβ1–42 level was reduced of
about 43 % (p<0.001) within 3 h and of 92 % after 20 h. The
analysis of cell lysates revealed that intracellular Aβ1–42 in-
creased in a time-dependent manner (Fig. 2c), thus confirming
that U-87 MG cell line is able to uptake Aβ from the extra-
cellular compartment. In particular, the concentration of inter-
nalized peptide increased linearly with time from 1 to 6 h
(Fig. 2d; r=0.93; p=0.02), raising about 5-fold (p<0.001).
Hpt Influence on Astrocyte-Mediated Aβ1–42 Clearance
As our results suggest that Hpt might interfere with Aβ1–42
binding to astrocytes, we investigated whether Hpt affects the
uptake of this peptide. To this aim, U-87 MG were incubated
with 5 μMAβ1–42, in the absence or presence of 1.6 μMHpt,
for different times (1.5–20 h). Aliquots of supernatants and
cell lysates were then analyzed both by immunoblotting and
by ELISA for measuring, at each time point, the amount of
Aβ1–42. Western blotting analysis demonstrated a significant
time-dependent decrease in soluble Aβ1–42 in the cell culture
supernatant (Fig. 3a), which was affected by Hpt. Indeed, a
higher amount of Aβ1–42 was detected in the supernatants
collected from cells incubated with 1.6 μM Hpt for 1.5, 3, or
Fig. 1 Aβ binding to astrocytes. a U-87 MG (15,000 cells/well) were
fixed into the wells of a 96-well plate and then incubated with different
concentrations (0.5–20 μM) of Aβ1–42. The amount of Aβ bound to cells
was detected bymouse anti-Aβ IgG 6E10 IgG andGAM-HRP, measured
as absorbance at 492 nm, and reported as percentage of the value obtained
with 20 μMAβ1–42 (assumed as 100 % of Aβ binding to cells). Samples
were processed in triplicate. Data were expressed as mean±SEM versus
μmolar concentration. One representative of at least three different ex-
periments is represented. b U-87 MG (15,000 cells/well) were fixed into
the wells of a 96-well plate and then incubated with mixtures containing
4 μMAβ1–42 and different amounts of Hpt (0–6 μM). The amount of Aβ
bound to cells was measured by incubation with mouse anti-Aβ IgG
6E10 IgG, followed by GAM-HRP and color development at 492 nm.
Data are reported as percent of the value obtained by incubation in the
absence of Hpt (assumed as 100 % of Aβ binding), and expressed as
mean±SEM. One representative of at least three different experiments is
represented
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6 h compared to those from cells incubated in the absence of
Hpt, thus suggesting that, within this time interval, the remov-
al of Aβ1–42 from the culture medium is influenced by the
presence of Hpt. Accordingly, the peptide concentration,
assessed by ELISA, was higher (1.6±0.08-fold, p<0.001) in
the supernatant collected after 1.5, 3, or 6 h of incubation with
Aβ1–42 and Hpt than in that from cells incubated with Aβ1–42
alone (Fig. 3b). In particular, the level of Aβ1–42 was reduced
of about 34 % (p=0.01) within 1.5 h in the absence of Hpt,
while it was unchanged, compared to time zero, in the pres-
ence of Hpt. Further Aβ1–42 concentration linearly decreased
from 1.5 to 6 h of incubation in the absence of Hpt (Fig. 3b; r=
−0.95, p=0.04), and from 1.5 to 20 h of incubation in the
presence of Hpt (Fig. 3b, r=−0.97, p=0.03). The analysis of
cell lysates by immunoblotting showed a time-dependent
increase in intracellular Aβ1–42 (Fig. 3c), which was affected
by the presence of Hpt. Indeed, the amount of peptide inter-
nalized raised until 6 h, when cells were incubated with
peptide alone (Fig. 3c), and until 3 h when cells were incu-
bated in the presence of Hpt. In particular, ELISA revealed
that the concentration of internalized peptide increased (about
2-fold; P<0.001) after 6 h of incubation in the absence of Hpt
compared to 1.5 h, but did not further change after 20 h
(Fig. 3d). Conversely, when cells were incubated with Hpt, a
mild increase in the level of internalized peptide (about
1.2-fold; P=0.02) was detected after 3 h when compared
to 1.5 h, and no change was found after 6 h. Further, the
concentration of peptide was significantly reduced (about
1.3-fold, P=0.02; Fig. 3d) after 20 h of incubation in
comparison to 3 h. These results demonstrate that Hpt
interferes with Aβ1–42 internalization by astrocytes. In
order to examine the aggregation state of Aβ, in absence
or in the presence of Hpt, a control experiment was
performed, in the same experimental conditions, by incu-
bating (0–20 h) 5 μM Aβ1–42 in DMEM without cells. As
shown in Figure S1, peptide aggregates were not clearly
detected in mixtures incubated for 1.5–6 h, both in the
absence and presence of Hpt. Conversely, in the mixture
incubated 20 h without Hpt, a smear of Aβ1–42 aggregates
was revealed, and this aggregate formation was highly
limited in the presence of Hpt, thus confirming that Hpt
contributes to inhibit peptide aggregation.
Fig. 2 Aβ1–42 uptake by U-87 MG cell line. U-87 MG (96-well plates;
15,000 cells/well) were incubated (1, 1.5, 3, 6, or 20 h, 37 °C) in DMEM
containing 5 μM Aβ1–42. At each time point, media samples and cell
lysates were collected and analyzed by Western blotting (a, c), and by
ELISA (b, d) for measuring Aβ concentration. a Representative Western
blot of cell culture supernatants. Samples were fractionated by 16% SDS-
PAGE, under denaturing but non reducing conditions followed by West-
ern blotting. Immunocomplexes were detected by mouse anti-Aβ IgG
6E10 IgG and GAM-HRP. bRepresentative ELISA titration of Aβ in cell
culture supernatants. Aβ concentration, in cell culture supernatants col-
lected at each time point, was measured bymouse anti-Aβ IgG 6E10 IgG,
followed by GAM-HRP, and color development at 492 nm. The calibra-
tion curve was obtained by assaying the immunoreactivity of 0.05–0.1-
0.25–0.50–0.75–1.0–2.0 ng of commercial Aβ standard. Samples were
processed in triplicate. Data were expressed as mean±SEM. c Represen-
tative Western blot of cell lysates. Samples were fractionated by 16 %
SDS-PAGE, under denaturing but non reducing conditions followed by
Western blotting. Immunocomplexes were detected by mouse anti-Aβ
IgG 6E10 IgG and GAM-HRP. d Representative ELISA titration of
intracellular Aβ. Aβ concentration, in cell lysates collected at each time
point, was measured by mouse anti-Aβ IgG 6E10 IgG, followed by
GAM-HRP, and colour development at 492 nm. The calibration curve
was obtained by assaying the immunoreactivity of 0.05–0.1−0.25–0.50
−0.75–1.0–2.0 ng of commercial Aβ standard. Samples were processed
in triplicate. Data were reported as microgram of peptide per microgram
of protein, and expressed as mean±SEM. For each panel, one represen-
tative of at least three different experiments is represented
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In order to further investigate the dose effect of Hpt on
Aβ1–42 clearance, U-87 MG were incubated with 5 μMAβ1–
42 and different amounts of Hpt (0–3 μM) for 3 h. As detected
by immunoblotting, the amount of peptide in cell culture
supernatants increased with the increase in Hpt concentration
(Fig. 4a, on the left). In agreement with this result, the level of
Aβ1–42 internalized decreased as Hpt concentration in the
incubation mixture raised (Fig. 4b, on the left). In detail, the
peptide level in the supernatants was found, by ELISA, sig-
nificantly higher (P<0.001; Fig. 4a, on the right) in the
presence of Hpt, at any assayed concentration (1.2-, 1.9-,
and 2.2-fold in the presence of 0.5, 1.6, and 3 μM protein,
respectively). The amount of internalized peptide was lower
(P<0.01 Fig. 4b, on the right) in the presence of Hpt, at any
assayed concentration (1.3-, 1.6-, and 3.5-fold in the presence
of 0.5, 1.6, and 3 μM protein, respectively).
Hpt effect on Aβ1–42 clearance was then compared with
that of another extracellular chaperone, ApoE, which was
previously reported to influence Aβ clearance by astrocytes
(Verghese et al. 2013). U-87 MG were incubated (1.5–20 h)
with 5 μMAβ1–42, in the absence or presence of 1.6 μMHpt,
or 1.6 μM LipoE3, or 1.6 μM Hpt and 1.6 μM LipoE3.
Aliquots of supernatants and cell lysates were then analyzed
both by immunoblotting and by ELISA for measuring the
amount of Aβ1–42. Western blotting analysis demonstrated
that, at each time point, the amount of Aβ1–42 was lower in
the cell culture supernatant collected from cells incubated with
peptide alone (Figure S2, panel A) than in the supernatants
obtained from cells incubated in the presence of Hpt, or
LipoE3, or Hpt and LipoE3. In particular, the peptide concen-
tration, assessed by ELISA, was higher in the supernatant
collected after 1.5, 3, 6, or 20 h in the presence of Hpt (1.54
±0.01-fold,P<0.01), or LipoE3 (1.86±0.05-fold, P<0.01), or
Hpt and LipoE3 (2.25±0.09-fold, p<0.001) than in that from
cells incubated with Aβ1–42 alone (Figure S2, panel b).
Further, the peptide concentration was higher in the superna-
tant collected after incubation in the presence of both proteins
than in that from cells incubated with Hpt alone (p<0.001), or
Fig. 3 Hpt influence on astrocyte-mediated Aβ1–42 clearance. U-87 MG
(96-well plates; 15,000 cells/well) were incubated (1.5, 3, 6, or 20 h,
37 °C) in DMEM containing 5 μMAβ1–42, in the absence or presence of
1.6 μM Hpt. At each time point, media samples and cell lysates were
collected and analyzed byWestern blotting (a, c) and by ELISA (b, d) for
measuring Aβ concentration. a Representative Western blot of cell cul-
ture supernatants. Samples were fractionated by 4–20 % SDS-PAGE,
under denaturing but non-reducing conditions followed by Western blot-
ting. Immunocomplexes were detected by mouse anti-Aβ IgG 6E10 IgG
and GAM-HRP. b Representative ELISA titration of Aβ in cell culture
supernatants. Aβ concentration, in cell culture supernatants collected at
each time point, was measured by mouse anti-Aβ IgG 6E10 IgG, follow-
ed by GAM-HRP, and color development at 492 nm. Open bar Samples
from cells incubated with 5 μM Aβ1–42. Full bar Samples from cells
incubated with 5μMAβ1–42 and 1.6 μMHpt. Samples were processed in
triplicate. Data were expressed as mean±SEM. Significance of differ-
ences is shown. ***p<0.001. c Representative Western blot of cell
lysates. Samples were fractionated by 4–20 % SDS-PAGE, under dena-
turing but non reducing conditions followed by Western blotting.
Immunocomplexes were detected by mouse anti-Aβ IgG 6E10 IgG and
GAM-HRP. d Representative ELISA titration of intracellular Aβ. Aβ
concentration, in cell lysates collected at each time point, was measured
by mouse anti-Aβ IgG 6E10 IgG, followed by GAM-HRP, and color
development at 492 nm. Open bar Samples from cells incubated with
5 μMAβ1–42. Full bar Samples from cells incubated with 5 μMAβ1–42
and 1.6μMHpt. Samples were processed in triplicate. Data were reported
as microgram of peptide per milligram of protein, and expressed
as mean±SEM. Significance of differences is shown. *p<0.05;
***p<0.001. For each panel, one representative of at least three
different experiments is represented
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with LipoE alone (p<0.05). Our results suggest that both
proteins act reducing the removal of Aβ1–42 from the culture
medium and demonstrate that LipoE effect was significantly
higher (p<0.05) than Hpt effect within 3 h of incubation.
Accordingly, the amount of peptide internalized was higher
(p<0.001) when cells were incubated with peptide alone
(Figure S2, panel c) than after incubation with Hpt, or
LipoE3, or Hpt and LipoE3, at each time point.
Aβ Effect on Cell Survival in the Presence of Hpt Aβ is toxic
towards various cultured cerebral cells including neurons
(Pike et al. 1993; White et al. 1998; Manelli et al. 2007) and
astrocytes (Brera et al. 2000). Aβ-induced cell dysfunction
and death was suggested to strongly depend on the peptide
ability to interact with plasma membrane (Williams and
Serpell 2011). Since we found that Hpt interferes with Aβ
uptake by astrocytes, we investigated whether Hpt might
hence modulate its cytotoxic effect.
Aβ1–42 concentrations affecting U-87 MG survival were
determined in a preliminary experiment, by incubating cells
(24 h) with different amounts of peptide (0–15 μM). As
shown in Fig. 5a, Aβ1–42 treatment decreased the cell survival
in a dose-dependent manner. In particular, the treatment with 3
or 6 μM Aβ1–42 reduced cell viability to 77 % (p=0.04) or
55 % (p=0.003), respectively. Data were analyzed by non-
linear regression, and the EC50 value was 13.8 μM.
The Aβ1–42 concentration 6 μM was chosen for further
experiments, carried out by incubating U-87 MGwith Aβ1–42
Fig. 4 Effect of Hpt concentration on astrocyte-mediated Aβ1–42 clear-
ance. U-87 MG (96-well plates; 15,000 cells/well) were incubated (3 h,
37 °C) in DMEM containing 5 μMAβ1–42 and different amounts of Hpt
(0, 0.5, 1.6, or 3 μM). Media samples and cell lysates were analyzed by
Western blotting (left) and by ELISA (right) for measuring Aβ concen-
tration. a left Representative Western blot of cell culture supernatants.
Samples were fractionated by 4–20 % SDS-PAGE, under denaturing but
non-reducing condi t ions fol lowed by Western blot t ing .
Immunocomplexes were detected by mouse anti-Aβ IgG 6E10 IgG and
GAM-HRP. rightRepresentative ELISA titration of extracellular Aβ. Aβ
concentration in cell culture supernatants was measured by mouse anti-
Aβ IgG 6E10 IgG, followed by GAM-HRP, and color development at
492 nm. Open bar Samples from cells incubated with 5 μMAβ1–42. Full
bar Samples from cells incubated with 5 μM Aβ1–42 and Hpt. Samples
were processed in triplicate. Data were expressed as mean±SEM.
Significance of differences is shown. ***p<0.001 vs 0 μM Hpt.
#p<0.05, ##p<0.01. b left Representative Western blot of cell lysates.
Samples were fractionated by 4–20 % SDS-PAGE, under denaturing but
non reducing condi t ions fol lowed by Western blot t ing.
Immunocomplexes were detected by mouse anti-Aβ IgG 6E10 IgG and
GAM-HRP. right Representative ELISA titration of intracellular Aβ. Aβ
concentration in cell lysates was measured by mouse anti-Aβ IgG 6E10
IgG, followed by GAM-HRP, and color development at 492 nm. Open
bar Samples from cells incubated with 5 μM Aβ1–42. Full bar Samples
from cells incubated with 5 μMAβ1–42 and Hpt. Samples were processed
in triplicate. Data were reported as microgram of peptide per milligram of
protein and expressed as mean±SEM. Significant differences are shown.
**p<0.01 vs 0 μM Hpt; ***p<0.001 vs 0 μM Hpt. #p<0.05;
###p<0.001. For each panel, one representative of at least three different
experiments is represented
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in the presence of different amounts of Hpt (0–1.2 μM). MTT
analysis demonstrated that the treatment with 6 μM Aβ re-
duced cell metabolic activity to 51.3±3.8 % of the control (p=
0.001), and this activity was significantly higher (p≤0.05;
Fig. 5b) when incubation with the peptide was performed in
the presence of Hpt. In particular, it was restored to 69.3±1 %
of the control (p<0.05) by 0.3 μM Hpt, to 94.4±3.4 % of the
control (p<0.001) by 0.6 μM Hpt, and it was completely
rescued when treatment was carried out in the presence of
1.2μMHpt. In agreement with this result, Crystal Violet assay
demonstrated that cell survival was restored to 87±3.1 % and
to 97.8±2.8 % of the control (p=0.001) by 0.6 and 1.2 μM
Hpt, respectively. These data suggest that Hpt, by binding Aβ,
might play a protective effect, by limiting the peptide-
dependent impairment of cell metabolic activity and survival.
Hpt Synthesis and Secretion by U-87 MG
Aβ peptides were reported to activate astrocytes and promote
secretion of inflammatory mediators, which in turn contribute
to the pathogenesis of neurodegenerative disorders, such as
AD (Wyss-Coray et al. 2003; Carrero et al. 2012; Medeiros
and Laferla 2013). Hence, we investigated whether Aβ may
influence Hpt production by astrocytes as well. U-87MG cells
were incubated (10 h) in DMEM containing different amounts
of Aβ1–42 (0, 3, or 6 μM), and aliquots of supernatants and
cell lysates were then analyzed by electrophoresis and
Western blotting. Hpt was detected in both supernatants and
cell lysates collected from cells not exposed to Aβ1–42, thus
suggesting that these cells synthesize Hpt (Fig. 6a and b, lane
1). The treatment with 3 μM Aβ1–42 did not affect Hpt
production. Conversely, the supernatants collected from cells
treated with 6 μM Aβ1–42 showed a higher amount of Hpt
(about 1.6-fold, p=0.01; Fig. 6a, lane 3) compared to super-
natants from control cells. Accordingly, Hpt level in lysates
from cells treated with 6 μM Aβ1–42 was higher (1.8-fold,
P<0.01; Fig. 6b, lane 3) than in those from untreated cells.
These results suggest that Aβ1–42 promotes Hpt synthesis and
secretion by astrocytes.
Discussion
Due to their proximity with senile plaques and to their capac-
ity to internalize and degrade Aβ deposit, astrocytes were
suggested to play an important role in AD pathology, although
the endocytic pathways in these cells are poorly understood
(Funato et al. 1998; Thal et al. 2000; Lasagna-Reeves and
Kayed 2011; Thal 2012). In order to find new therapeutic
strategies, it is important to understand factors that govern
Aβ metabolism and how they lead to Aβ accumulation. The
amount of Aβ accumulated in the extracellular space depends
on the balance between its synthesis and its clearance (Huang
and Mucke 2012). Many proteins have been shown to bind
Aβ and influence its aggregation and clearance. The discov-
ery of abundant extracellular chaperones that are capable of
influencing early events in the amyloid cascade has generated
considerable interest in their role in disease pathogenesis and,
potentially, as targets for intervention. Besides ApoJ and
ApoE, other plasma and CSF proteins, such asα2 macroglob-
ulin, Hpt, serum amyloid-P, and transthyretin, have been
identified as extracellular chaperones, able of influencing
Aβ aggregation and/or toxicity (Veerhuis et al. 2003;
Yerbury et al. 2005; Wilson et al. 2008). It is remarkable
how often these chaperones have been identified as altered
in AD. Very recently, various research groups reported, by
different experimental approaches, that some AAPs, particu-
larly ApoJ and ApoE, can negatively affect, in specific con-
ditions, Aβ clearance by glial cells (Kim et al. 2011; Bien-Ly
et al. 2012; Verghese et al. 2013; Mulder et al. 2014).
We here provide evidence, for the first time, that Hpt
significantly inhibits the uptake of Aβ by astrocyte cell line.
Fig. 5 Aβ effect on cell survival in the presence of Hpt. A. U-87 MG
were incubated into 96-well plate (20 h; 5000 cells per well) in DMEM
containing different amounts of Aβ1–42 (0, 0.5, 1.5, 3, 6, 10, or 15 μM).
Cell survival was evaluated by MTT assay, and it was expressed as
percentage of viability of the control (cells cultured in the absence of
Aβ; open square). Significant differences from control are indicated
(*p<0.05; **p<0.01). Data are reported as mean±SEM. b U-87 MG
were incubated into 96-well plate (20 h; 5000 cells per well) in DMEM
containing 6 μM Aβ1–42 and different amounts of Hpt (0, 0.15; 0.3, 0.6,
or 1.2 μM; bars with vertical line). Cell survival was evaluated by MTT
assay (on the left) and by Crystal Violet assay (on the right) and expressed
as percentage of viability of the control (cells cultured without Aβ and
Hpt; open bar). Significant differences from cells treated by Aβ1–42 (full
bar) are indicated (*p<0.05; **p<0.001; ***p<0.0001). Data are report-
ed as mean±SEM
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Hpt was reported to bind Aβ (Yerbury et al. 2005; Spagnuolo
et al. 2014b) and reduce peptide aggregation (Yerbury et al.
2009). We actually found that Hpt was able to impair peptide
aggregation in our experimental conditions (Aβ/Hpt molar
ratio 3:1; data not shown). Therefore, Hpt may influence Aβ
uptake from astrocytes by preventing the binding of Aβ on
cell surface and/or by reducing peptide aggregation. As matter
of the fact, it was recently reported that the ability of U-87 to
internalize aggregated Aβ exceeds that of monomeric Aβ
(Mulder et al. 2014). Whether Hpt acts either by competing
with Aβ for the same pathways or through other effects on Aβ
clearance requires further studies. Importantly, we demon-
strate here that Hpt might play a protective effect by inhibiting
Aβ internalization. Indeed our data demonstrate that Hpt
prevents the peptide-dependent impairment of cell metabolic
activity, thus preserving glial cell survival. This neuroprotec-
tive action might either depend on the Hpt ability of binding
Aβ, which could interfere with the peptide interaction with its
receptor, and/or on the Hpt ability of reducing peptide aggre-
gation. It cannot be excluded that Hpt impairs Aβ entry in
astrocytes while promoting its clearance through BBB or
other brain cells such as microglia, or endothelial cells.
Beneficial effects of Hpt were already reported, since it plays
a critical role in defending neurons from damage, by
neutralizing iron-rich hemoglobin released into the brain pa-
renchyma, after intracerebral hemorrhage (Zhao et al. 2009).
In addition, we previously demonstrated that Hpt is able to
protect apolipoprotein A-I and ApoE from oxidative damage
(Salvatore et al. 2007, 2009). Although the exact role of Hpt in
AD pathology remains to be elucidated, our data suggest that a
local release of Hpt might contribute to modulate Aβ uptake
and clearance by astrocytes.
Age-related variations of Hpt might affect Aβ metabolism
and cell survival in brain. Indeed, we recently reported that
Hpt level significantly increases during aging in rat hippo-
campus, which is the region massively damage in AD
(Spagnuolo et al. 2014a). The increase in Hpt with age, in this
brain compartment, might affect the astrocyte ability to incor-
porate Aβ, thus influencing the extracellular concentration of
this peptide. This might promote Aβ aggregation pathways in
the long term but might also increase the stability of Aβ in the
extracellular compartment in situations in which the beneficial
physiological roles of this peptide are necessary for brain
health. Indeed, the dual role of Aβ is long far known, since
it can play a neuroprotective role, by promoting neuronal
growth and survival (Bishop and Robinson 2004; Giuffrida
et al. 2010), and also protecting against excitotoxic death (Luo
et al. 1996; Giuffrida et al. 2009), but, at high concentrations,
Fig. 6 Hpt synthesis and secretion by U-87 MG. U-87 MG were incu-
bated into 24-well plate (10 h; 100,000 cells/well) in DMEM containing
different amounts of Aβ1–42 (0, 3, or 6 μM). At the end of incubation,
media samples (a) and cell lysates (b) were analyzed by electrophoresis
on 15 % polyacrylamide gel, under denaturing and reducing conditions,
and Western Blotting. a Representative Western blot of cell culture
supernatants (on the left). Immunocomplexes were detected by rabbit
anti-human Hpt IgG and GAR-HRP. Quantitative densitometry of Hpt
was carried out and band intensities were calculated (shown on the right).
The data represent the mean±SEM. Significant difference from control
(cells cultured in the absence of Aβ; open bar) is shown. **p<0.01. b
Representative Western blot of cell lysates (on the left).
Immunocomplexes were detected by rabbit anti-human Hpt IgG and
GAR-HRP. After Hpt detection, the membrane was stripped for reprobing
with anti-β-actin. Quantitative densitometry of Hpt and β-actin was
carried out, and band intensities were calculated. Hpt concentration is
shown relative to β-actin level (arbitrary units, on the right). The data
represent the mean±SEM. Significant difference from control (cells
cultured in the absence of Aβ; open bar) is shown. **p<0.01
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it can cause neuronal degeneration in mature neurons
(Yankner et al. 1990). In addition, it was shown to serve a
double prooxidant/antioxidant role (Kontush et al. 2001;
Butterfield 2002; Nadal et al. 2008; Baruch-Suchodolsky
et al. 2009) and to bind and remove harmful substances by
blocking them in plaques (Bishop and Robinson 2002;
Robinson and Bishop 2002). Aβ ability to enhance synaptic
plasticity and memory was reported as well (Puzzo and
Arancio 2013). From these studies, the fascinating hypothesis
arises that, in the healthy brain, physiological Aβ concentra-
tions are necessary for the correct functioning of the cerebral
compartment.
Interestingly, U-87MG cell line is here reported to enhance
Hpt production and release when challenged with Aβ. This
finding suggests that these cells might undertake specific
pathways to produce extracellular chaperones, such as Hpt,
which are able to hold Aβ in the extracellular compartment
and, at the same time, limit its pathological aggregation. The
increase in Hpt level might affect brain pathophysiology,
modulating Aβ internalization and protecting cells from cho-
lesterol toxicity or oxidative stress. On the other hand, it
cannot be excluded that enhanced Hpt levels, by limiting
Aβ uptake by astrocytes, might represent a further way by
which inflammation worsens the onset and rate of progression
of neurodegeneration. We cannot assess, to date, whether the
positive effects of Hpt in brain outweigh the negative effects,
or vice versa. How exactly Hpt influences Aβ metabolism,
neuronal functions, and survival remains to be determined.
Furthermore, further studies are required to highlight whether
Hpt undergo changes during the onset and progression of AD.
The study of the risk of developing AD or the research of new
therapeutic strategies should be focused not only on the anal-
ysis of Aβ concentration but also on the level of critical
ligands, such as Hpt, able to influence peptide aggregation
or clearance.
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